microdosing glp 1 alzheimer's How GLP-1s Could Transform Treatment GLP-1R agonists protect against Alzheimer's

Lian LY (1998)

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Be alert for any psychiatric symptom changes, though evidence suggests GLP-1s dont worsen depression or anxiety

Subcutaneous injection addresses systemic inflammation: joints, skin, and autoimmune conditions

However, preclinical work and recent clinical studies suggest that this view may be incomplete and ignores potentially important contributions from GIP

Intensive insulin therapy, which may include mealtime plus basal insulin (1-3 times/day) or premixed insulin analogs (2-3 times/day), may be considered as part of the treatment strategy[1]